Adial Pharmaceuticals Stock (NASDAQ: ADIL)

Adial Pharmaceuticals (NASDAQ:ADIL) Stock, Quote.Headers.trade-ideas

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

ADIL

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal for Adial&#39;s upcoming Phase 3 trial.

EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder

Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results expected in Q4 2024 will inform Phase 3 clinical trial plans.

EXCLUSIVE: Adial Pharmaceuticals&#39; Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4

Why Does Coca-Cola Taste Different In Other Countries?

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AZTR

CLRB

FEIM

JAGX

RNAZ

Gold Moves Higher; Coca-Cola Increases FY24 Forecast

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $75 price target.

Price Target

Analyst Ratings

EXAS

Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target

Trump Media & Technology Group Shares Halted To The Upside; Stock Now Up 25.23%

Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has issued an invite for October. The invite named &#8216;Robinhood Presents: The Legend Awakens&#8216; said Robinhood will broadcast a live stream during which co-founder and CEO Vlad Tenev will <a target="_blank" href="https://go.robinhood.com/presents" rel="noreferrer noopener">introduce</a> new trading products.
The event is scheduled for October 16 at 6:30 PM ET.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40752830/robinhood-shifted-from-meme-stock-to-market-contender-amid-new-products-and-global-" rel="noreferrer noopener">Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock</a>.
In March, the company hosted Robinhood Presents: The New Gold Standard, and it introduced its first credit card, the Robinhood Gold Card.
The company said the credit card is exclusively for <a target="_blank" href="https://www.benzinga.com/news/24/03/37950775/robinhoods-new-3-cash-back-gold-card-unveiled-referral-champions-stand-to-win-a-genuine-precious-met" rel="noreferrer noopener">Robinhood Gold members</a>.
The Robinhood Gold Card has no annual or foreign transaction fees and offers a 3% cash back on all categories.
Earlier this month, Robinhood launched a share lending program in the U.K., allowing users to generate passive income. This <a target="_blank" href="https://www.cnbc.com/2024/09/04/robinhood-launches-stock-lending-product-in-the-uk.html" rel="noreferrer noopener">initiative</a> is part of the company&#8217;s broader strategy to strengthen its global market presence.
Recently, the company reported operating data for August, with total funded customers increasing to 24.3 million, up approximately 60,000 from July and one <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40781343/robinhood-markets-inc-reports-august-2024-operating-data" rel="noreferrer noopener">million year-over-year</a>.
Total assets under custody were up about 60% from year-over-year to $143.6 billion. Net Deposits were $3.3 billion at the end of the month.
Equity notional trading volumes were&nbsp;$96.2 billion, up 8% sequentially and 61% year-over-year.
Options contracts traded were 146.9 million, down 8% from July but up 37% year over year, and crypto notional trading volumes were&nbsp;$5.4 billion, up 2% from July but up 145% year over year.
Since January, the Robinhood stock has moved almost 80% higher and around 21% over the last month.
Price Action: HOOD stock is up 2.56% at $22.20&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40855784/uber-stock-spikes-as-ceo-praises-waymos-fully-autonomous-trips" target="_blank" rel="noreferrer noopener">Uber Stock Spikes As CEO Praises Waymo&#8217;s &#8216;Fully Autonomous Trips&#8217;</a></li>
</ul>
Photo via Shutterstock

Movers

Tech

HOOD

Robinhood Issues Invite For October 16 Event to Introduce New Trading Products

Canaccord Genuity analyst Austin Moeller maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $1.5 price target.

EVTL

Canaccord Genuity Maintains Buy on Vertical Aerospace, Maintains $1.5 Price Target

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 18.56% on an annualized basis producing an average annual return of 30.29%. Currently, Super Micro Computer has a market capitalization of $26.83 billion. 
Buying $100 In SMCI: If an investor had bought $100 of SMCI stock 15 years ago, it would be worth $5,290.53 today based on a price of $458.14 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726252350_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,300 Today

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has outperformed the market over the past 10 years by 2.0% on an annualized basis producing an average annual return of 12.79%. Currently, JPMorgan Chase has a market capitalization of $581.54 billion. 
Buying $1000 In JPM: If an investor had bought $1000 of JPM stock 10 years ago, it would be worth $3,389.16 today based on a price of $204.40 for JPM at the time of writing.
<h3>JPMorgan Chase's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726252346_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,400 Today

Trump Media & Technology Group Shares Resume Trade

Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) shares are trading higher today. On Thursday, the company announced that it would acquire Recorded Future for $2.65 billion, enhancing cybersecurity services with <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40832349/mastercard-expands-cyber-defense-with-2-65b-deal-for-recorded-future-whats-on-the-cards" rel="noreferrer noopener">real-time threat intelligence</a>.
This acquisition enhances Mastercard's cybersecurity services, strengthening the insights and intelligence crucial for securing the digital economy, including the payments ecosystem.
J.P.Morgan analyst Tien-tsin Huang writes that they see the acquisition as a positive development and note the price paid is reasonable for a high-quality asset <a target="_blank" href="https://www.benzinga.com/quote/MA/analyst-ratings" rel="noreferrer noopener">advanced in AI for threat intelligence</a>.
The analyst writes that Recorded Future excels in data ingestion and analysis, delivering actionable threat insights to clients.
Huang sees strong synergies with Mastercard, leveraging its extensive consumer and transactional dataset and enhancing growth through Mastercard&#8217;s deep partnerships with financial institutions, merchants, and other partners.
The analyst projects that Recorded Future could boost FY25 revenue by approximately 1ppt, or 3ppts within VAS&amp;S, and is likely to be accretive to VAS&amp;S revenue growth.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;BlackRock Long-Term U.S. Equity ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELT#NASDAQ">BELT</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40748559/alibaba-and-mastercard-team-up-to-offer-new-perks-for-us-business-owners" rel="noreferrer noopener">Alibaba and Mastercard Team Up To Offer New Perks for US Business Owners</a>
Price Action: MA shares are up 0.54% at $494.75 at the last check Friday.
Image: Unsplash/ CardMapr.nl
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40858482" target="_blank" rel="noreferrer noopener">Oracle Analysts Praise &#8216;Resilient, Sticky&#8217; Revenue Stream, AI Growth After CloudWorld Conference</a></li>
</ul>

Analyst Color

Equities

Large Cap

BELT

iShares Trust Dow Jones US Financial Services Index Fund

Mastercard's Cybersecurity Expansion: Analysts Highlight Synergies And Positive Revenue Impact By 2025

Canaccord Genuity analyst Susan Anderson maintains Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) with a Buy and maintains $14 price target.

COTY

Canaccord Genuity Maintains Buy on Coty, Maintains $14 Price Target

WIIM

Trump Media & Technology Group shares are trading higher after President Trump said he is not selling his shares of the company.

Tempus AI shares are trading higher after the company announced four abstracts were accepted for presentation at ESMO Congress 2024.

Trump Media & Technology Group Shares Halted To The Upside; Stock Now Up 12.53%

NUVL

Nuvalent shares are trading higher after  the company announced a cancer discovery publication highlighting design, pre clinical activity, and early clinical data of ALK-Selective Inhibitor NVL-655.

Trump Media & Technology Group Shares See Volume, Trump Says "No I'm Not Selling" When Asked About His Shares In The Co.

Homeowners have more <a href="https://www.benzinga.com/real-estate/24/06/39398524/home-sales-suffer-third-worst-month-in-the-last-10-years">real estate equity </a>than ever before, according to data from the federal government and an investment group.
Total homeowner&#8217;s equity in the U.S. reached $35.1 trillion in this year&#8217;s second quarter, data from the Federal Reserve <a href="https://fred.stlouisfed.org/series/OEHRENWBSHNO">showed</a>.
It fell as low as $29.8 trillion in the last quarter of 2022, but that is way above a most recent low of $8.22 trillion in the first quarter of 2012, according to the Fed data. 
Homeowner&#8217;s equity has skyrocketed 15,845% over the past seven decades from $219 billion in 1951.
Another indicator of homeowner wealth is that households have the least mortgage debt relative to their property value in almost 70 years as homes appreciate in value and homeowners pay down their mortgages, according to data from Bespoke Investment Group.
Read Also: <a href="https://www.benzinga.com/real-estate/24/06/39465243/u-s-home-sales-decline-for-third-month-as-record-prices-pose-persistent-affordability-challenges-dur">U.S. Home Sales Decline For Third Month As Record Prices Pose Persistent Affordability Challenges During Key Selling Season</a>
Household mortgage debt as a percentage of real estate value has halved from 53% in December 2011 to 27.3% in 2021.
&#8220;Consumer balance sheets are rock solid, which is another reason to question the narrative of impending recession,&#8221; Bespoke said.
Mortgage rates fell to <a href="https://www.benzinga.com/markets/24/09/40843840/mortgage-rates-fall-to-lowest-level-since-february-2023">their lowest point</a> in more than 18 months last week. That&#8217;s encouraging homebuyers to refinance the amount they have left to pay on their home loans.
The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($766,550 or less) decreased to 6.29 percent from 6.43 percent, marking the sixth straight week in declining rates, according to the Mortgage Bankers Association (MBA).
Price Action: Mortgage lenders saw losses and gains into Friday&#8217;s early-afternoon trading.
<ul>
<li>Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) rose 6.11% to $19.90</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) slipped 0.46% to $38.60</li>
<li>Better Home &amp; Finance Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) gained 1.04% to $16.50</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40549967/two-things-the-latest-home-sales-numbers-say-about-the-real-estate-market">Two Things The Latest Home Sales Numbers Say About The Real Estate Market</a></li>
</ul>
Image: Pixabay

Federal Reserve

Real Estate

BETR

Homeowners Have Never Been Richer, Data Shows: 'Another Reason To Question Recession Narrative'

Jefferies analyst Akash Tewari maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Hold and raises the price target from $90 to $96.

BNTX

Jefferies Maintains Hold on BioNTech, Raises Price Target to $96

BofA Securities analyst Ronald J. Epstein reiterated a Neutral rating on Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>),<a target="_blank" href="https://www.benzinga.com/quote/BA/analyst-ratings" rel="noreferrer noopener"> with a price forecast of $200.</a>
The analyst views Boeing as particularly vulnerable, noting that the company has delayed its 737 production rate increase from 42 per month, originally set for September 2024, to March 2025.
A prolonged strike could further worsen the company&#8217;s current difficulties, Epstein added.
However, if the Spirit AeroSystems strike and subsequent contract negotiations set a precedent, the strike could potentially be resolved in as little as a week, Epstein adds.
The analyst forecasts that Boeing may need to offer additional concessions, possibly approaching the IAM&#8217;s original demand for a 40% wage increase.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40853982/boeings-stock-falls-as-33-000-aircraft-assembly-workers-strike" rel="noreferrer noopener">Boeing&#8217;s Stock Falls As 33,000 Aircraft Assembly Workers Strike</a>
The analyst highlights that both CEO Kelly Ortberg and COO Stephanie Pope have fired off internal memos to Boeing staff, trying to cool down strike sentiments.
Pope touted the proposed contract as Boeing&#8217;s best ever, emphasizing the 25% wage increase despite the company&#8217;s hefty $60 billion debt, the analyst highlights.
Meanwhile, Kelly&#8217;s memo admitted that Boeing is grappling with a rough patch, partly due to past blunders, and warned that a strike could derail their hard-fought recovery.
According to the analyst, Boeing now has the onus to act, resolve the issues, and prevent additional &#8220;disruptions.&#8221;
Meanwhile, Boeing shares are trading lower after workers rejected the proposed labor contract, leading to a strike. Moody&#8217;s placed the company&#8217;s ratings on review for downgrade amid concerns.
According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, BA stock has lost 25% in the past year. Investors can gain exposure to the stock via iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) and Gabelli Commercial Aerospace and Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCAD#NYSE">GCAD</a>).
Price Action: BA shares are trading lower by 3% to $157.87 at last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40847259/boeing-workers-strike-at-midnight-threatens-aircraft-production-as-financial-risks-loom-after-30" target="_blank" rel="noreferrer noopener">Boeing Worker&#8217;s &#8216;Strike At Midnight&#8217; Threatens Aircraft Production As Financial Risks Loom After 30,000 Workers Vote For Industrial Action</a></li>
</ul>

GCAD

iShares Dow Jones US Aerospace & Defense Index Fund

Boeing May Need To Offer Additional Concessions To End Strike Despite Multi-Billion Dollar Debt: BofA Analyst

Former U.S. President Donald Trump has experienced <a href="https://www.benzinga.com/real-estate/24/08/40666407/what-stocks-does-donald-trump-own-new-financial-disclosure-revealed">a significant downturn</a> in his cryptocurrency portfolio, losing $19.27 million over the past three months, according to data from blockchain intelligence firm Arkham.
What Happened: As of Sept. 13, Trump&#8217;s total crypto holdings are <a href="https://platform.arkhamintelligence.com/explorer/entity/donald-trump">valued</a> at $5,868,659.51, a stark contrast to the $25.16 million recorded on June 6, representing a 76.6% decrease.
This revelation comes at a pivotal moment for Trump, as he and his family prepare to launch a controversial cryptocurrency project called <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40853339/donald-trumps-son-barron-is-his-chief-defi-visionary-but-the-real-mastermind-behind-world-">World Liberty Financial on Sep. 16.</a>
The announcement, made on Trump&#8217;s social media platform, has stirred both political and financial circles. 
In a video post, Trump declared, &#8220;We&#8217;re embracing the future with crypto and leaving the slow and outdated big banks behind,&#8221; signaling a dramatic shift from his previous stance on digital currencies.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read:<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857676/what-changed-federal-reserve-may-take-a-bigger-50-basis-points-rate-cut-bite-next-week-mar"> &#8216;What Changed?&#8217; — Federal Reserve May Take A Bigger 50 Basis Points Rate Cut Bite Next Week, Market Odds Imply</a>
Trump&#8217;s portfolio comprises various cryptocurrencies, with Maga Memecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) token leading at $1.41 million, followed closely by Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) at $1.19 million.
Other significant holdings include (CRYPTO: GUA), Wrapped Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WETH</a>), TROG (CRYPTO: TROG), USD Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), MAGAA (CRYPTO: MAGAA), and CONAN (CRYPTO: CONAN), each contributing to his diverse crypto investments. 
The most substantial losses were seen in TROG and TRUMP tokens, which plummeted by 95.73% and 79.24% respectively, while Ethereum and Wrapped Ethereum also saw considerable drops of around 35-36%.
This shift in Trump&#8217;s crypto stance aligns with his recent advocacy for digital currencies to be &#8220;made in the USA,&#8221; emphasizing the need to counter <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39817200/donald-trump-comments-on-crypto-pivot-if-we-dont-do-it-china-will">China&#8217;s growing influence in the field</a>.
In July, he warned that the United States must embrace digital currencies to prevent China from dominating the sector, a stark contrast to his earlier characterization of Bitcoin as a &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39801662/the-real-reason-why-donald-trump-has-pivoted-towards-crypto">scam</a>&#8221; and a &#8220;disaster waiting to happen.&#8221;
Trump&#8217;s evolving position on cryptocurrencies reflects a broader strategy to position the U.S. as a leader in emerging technologies. 
This move has garnered support from the crypto industry and stands in sharp contrast to the Biden administration&#8217;s regulatory approach.
What&#8217;s Next: Investors and enthusiasts seeking deeper insights into the future of digital assets can look forward to Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry leaders will convene to discuss trends, regulations, and the potential trajectory of cryptocurrencies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857265/kraken-pushes-back-against-sec-lawsuit-demands-jury-trial">Kraken Pushes Back Against SEC Lawsuit, Demands Jury Trial</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$TRUMP

$USDC

$WETH

Here's How Much Donald Trump's Crypto Portfolio Is Down From The Top (Spoiler: It's Millions And Millions Of Dollars)

VMAR

Vision Marine Technologies Shares Resume Trade

CVAC

CureVac shares are trading higher after the company presented its CVGBM cancer vaccine results from its Phase 1 study of Glioblastoma at the ESMO 2024 Congress.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: 



<ul><li>Massive sums of capital to begin with</li>



<li>Decades of time and more modest sums of capital</li>



<li>More modest sums of capital and a combination of risk and luck</li>
</ul>We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. 



Investing in sub-$2 stocks is very risky. Direct the majority of your capital toward more stable, conservative approaches. Direct much less capital to these riskier stocks that will require a combination of risk and luck.



All of the stocks discussed below cost less than $2 per share meaning $1,000 will get you at least 500 shares. Those 500 or more shares have the potential to appreciate in value above $10,000 by 2025.



<h2>Reliance Global (RELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) is a business group that acquires and manages retail insurance agencies in the United States. I chose to lead off the article with this stock specifically because it is not a pharma firm or another biotech stock. The purpose in doing so is not to say that <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are bad. Instead, it is to show there are plenty of 10X <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> outside of the biotech sector.



As I mentioned, there is a lot of risk in investing in shares of stocks trading at these levels. Investing in Reliance Global will be no different. The stock has lost roughly 95% of its value over the last 12 months. It currently trades for 25 cents per share. That should logically raise a lot of red flags for investors. However, there are reasons to believe that the company can rebound from here. 



Primarily, the company recently announced a definitive agreement to acquire Spetner Associates. The integration of Spetner Associates is expected to double Reliance Global&rsquo;s annual revenues to $28 million.&nbsp;



That news was <a href="https://www.globenewswire.com/news-release/2024/05/15/2882429/0/en/Reliance-Global-Group-Announces-Game-Changing-Acquisition-of-Spetner-Associates-Projected-to-Double-Company-s-Revenue.html">announced on May 15</a> and sent share prices drastically higher. The bet at this time is the integration of the new partner will again significantly increase revenues. Despite the obvious risk, that&rsquo;s the clear narrative behind investing in Reliance Global.



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>) is a biotech stock focused on the treatment of lung diseases that lead to fibrosis, or scarring of the lung tissue.



It appears to be among the better biotech stocks to bet on at this time. The company&rsquo;s lead candidate drug, Efzofitimod, has received FDA and EU orphan drug designation. That effectively fast tracks its development for the treatment of sarcoidosis and scleroderma.



The company also has a deal in place with Japan&rsquo;s Kyorin Pharmaceutical worth up to $175 million To develop and commercialize Efzofitimod in Japan. The company&rsquo;s pipeline of drugs extends beyond Efzofitimod with that drug being the clear catalyst overall.&nbsp;



LIFE shares currently trade for $1.76 and <a href="https://stockanalysis.com/stocks/life/forecast/">have a consensus target price above $25</a>.&nbsp;



The company continues to release <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-positive-dsmb-review-efzofitimod">positive news about its lead candidate drug</a>. That is not the only good news surrounding aTyr Pharma. The company also announced inducement grants that allowed <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-4">two employees to purchase 9,400 shares of stock at $1.86</a>. That suggests there is an immediate upside in LIFE stock at the moment.



<h2>BioLineRx (BLRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>BioLineRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) is a company attempting to commercialize therapeutics for the treatment of various cancers and rare diseases including sickle cell disease. The company&rsquo;s recent announcements around those projects deserve particular attention and make the stock attractive.



BioLineRx truly does look like a biotech stock that&rsquo;s about to move much higher. Interested investors should read this <a href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html">recent portfolio update from May 28</a>. The company&rsquo;s FDA-approved multiple myeloma treatment, Aphexda, is growing steadily in its first full quarter of post-approval adoption.&nbsp;



The drug is quickly making its way into the network of transplant centers and is placed at 26% of all institutions in the U.S. currently. BioLineRx expects that number to rise to 35% by the end of the second quarter and could rise to 60% by the end of the year.



The biotech is currently running at a slight net loss of $0.7 million but benefits from continued progress in clinical trials relating to other diseases including sickle cell disease. In short, there seem to be multiple reasons to bet on BLRX stock at the moment.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div>Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) stock represents a company that builds fully autonomous security robots. Honestly, its products look a bit like something out of a dystopian future movie from the &rsquo;90s. Despite that, Knightscope&rsquo;s progress makes it very interesting for investors.



The company hasn&rsquo;t released highly detailed financial statements but the most recent indication that we have is from March. That report <a href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-2023-estimated-revenues-increase-128-128-million">showed revenues increased by 128% to $12.8 million </a>during 2023. The report also includes some images of the company&rsquo;s AI-enabled security robots that are a bit cyberpunk and Robocop.&nbsp;



The company released another report days later updating the company&rsquo;s financial position. It showed that the company&rsquo;s net loss narrowed from $25.6 million to $22.1 million in 2023. It also noted the company has 10,000 machines in its network across the United States and the company plans to reduce its payroll expense by 30% this year.



The company has since <a href="https://ir.knightscope.com/news-and-events/news">won multiple contracts and deployed multiple tranches </a>of robots.&nbsp;



<h2>Adial Pharmaceuticals (ADIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) is a company working to address addiction disorders that are quite rampant across society. The reason to believe in the stock lies in its lead candidate drug, AD04. That drug is intended to treat alcohol use disorder, opioid use disorder and a host of potential other drug dependencies.&nbsp;



The company has identified a range of genetic phenotypes that respond to AD04. Adial Pharmaceuticals estimates that represents a $40 billion opportunity in the U.S. alone.



The company also secured patent rights protecting the ability of that drug to target specific gene sequences relating to various drug dependency disorders.&nbsp;



The company is clearly very interesting for its positioning relative to various substance dependencies and their overall socioeconomic burden. However, potential investors should also be aware the company&rsquo;s&nbsp;current liquidity only covers the company through the first quarter of 2025. Regardless, substance disorder pharmaceutical firms are a rapidly growing sub-sector within the industry and Adial Pharmaceuticals could certainly emerge as a winner.&nbsp;



<h2>Society Pass (SOPA)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div>Investors interested in the outsized growth prospects in Southeast Asia should take a look at Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>). The company continues to build an ecosystem encompassing e-commerce and fintech worth understanding at least.



The <a href="https://www.globenewswire.com/news-release/2023/12/07/2792494/0/en/Society-Pass-Inc-Nasdaq-SOPA-Ascendiant-Capital-Issues-3Q-2023-Equity-Research-Update-3Q-Results-Show-Solid-Revenue-Growth-and-Maintains-Positive-Outlook-on-Growth-Prospects.html">most recent earnings report</a> from the third quarter of 2023 shows that revenues grew by 11%. Clearly, that&rsquo;s not the sort of outsized growth many seek from emerging market opportunities. Nevertheless, there are things to like about Society Pass. What I like is that the company has zero debt and $8 million in cash.&nbsp;&nbsp;



Despite a net loss of $3.9 million in the period, the company managed to report a modest gross profit of $600,000. The company also has a $40 million line of credit should that ultimately be necessary. That line of credit is an indication institutional investors see the overall opportunity represented by Society Pass. Much like Adial Pharmaceutical, Society Pass is interesting for operating within a high-growth sub-sector that may not get as much attention as it deserves.



<h2>Enviva (EVA)</h2>



<div><img width="300" height="200" src="https://investorplace.com/wp-content/uploads/2022/01/carbon-dioxide-1600-300x200.png" alt="Environmental pollution, environmental problem, smoke from the chimney of an industrial plant or thermal power plant against a cloudy sky"><div>Source: AYDO8 / Shutterstock.com</div></div>Investing in Enviva (NYSE:<a href="https://investorplace.com/stock-quotes/eva-stock-quote/">EVA</a>) stock will appeal to green investors&nbsp;and industrial investors looking for turnaround opportunities. The company produces sustainable wood pellets intended to provide a low-carbon alternative to fossil fuels.



While the company has some interesting, promising catalysts, it is going through a transition as it attempts to affect a turnaround. The most recent earnings reports &mdash; from November 2023 &mdash; gets into those details.



Most of the report focused on the appointment of the company&rsquo;s previous CFO to an interim CEO position. He is essentially tasked with turning around deepening losses and righting the course for Enviva. The <a href="https://ir.envivabiomass.com/news/news-details/2023/Enviva-Reports-3Q-2023-Results/default.aspx">fundamentals tell the story of a company in trouble</a>. Revenues fell by a modest 1.3% in that report while net losses more than quadrupled to $85.2 million.&nbsp;



The company has <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001592057/5aee415d-4604-4366-a34d-18c777395a61.pdf">not filed any subsequent financial reports</a> since November. It&rsquo;s clearly at risk of bankruptcy and restructuring. My sense is that the company&rsquo;s shares will trend downward but they certainly do <a href="https://stockanalysis.com/stocks/eva/forecast/">have the potential to 10X</a> nonetheless.&nbsp;



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/millionaire-makers-7-stocks-you-can-buy-for-2-that-can-10x-by-2025/">Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) just reported results for the fourth quarter of 2023.<ul><li>Adial Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -47 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/adil-stock-earnings-adial-pharmaceuticals-for-q4-of-2023/">ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an <a href="https://finance.yahoo.com/news/adial-pharmaceuticals-advances-second-cohort-123000025.html">update on its AD04 study</a>.



Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study. This comes after the success of its first cohort as a treatment for Alcohol Use Disorder (<a href="https://investorplace.com/stock-quotes/aud-stock-quote/">AUD</a>).



Adial Pharmaceuticals notes that this study started last month and is expected to reach completion during the fourth quarter of this year. The data from it will provide valuable insight into AD04&rsquo;s pharmacokinetic properties.



Adial Pharmaceuticals president and CEO Cary Claiborne said the following about the AD04 progress.




&ldquo;The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.&rdquo;




<h2>How This Affects ADIL Stock</h2>



News of the progression to a second cohort brings with it heavy trading of ADIL shares. This has more than 145 million units changing hands as of this writing. That&rsquo;s a massive surge compared to its daily average trading volume of about 154,000 shares.



ADIL stock is up 61.3% as of Tuesday morning.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market happenings worth diving into on Tuesday! That includes what&rsquo;s happening with shares of CrowdStrike&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>), Solventum&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/solv-stock-quote/">SOLV</a>) and Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>) stock today. You can catch up on all of these matters at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/crowdstrike-outage-update-everything-you-need-to-know-as-shutdowns-persist/">CrowdStrike Outage Update: Everything You Need to Know as Shutdowns Persist</a></li>



<li><a href="https://investorplace.com/2024/07/solv-stock-alert-solventum-pops-as-activist-investor-trian-capital-takes-stake/">SOLV Stock Alert: Solventum Pops as Activist Investor Trian Capital Takes Stake</a></li>



<li><a href="https://investorplace.com/2024/07/rivn-stock-ceo-apple-carplay-isnt-coming-to-rivian-evs-anytime-soon/">RIVN Stock CEO: Apple CarPlay Isn&rsquo;t Coming to Rivian EVs Anytime Soon</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-adial-pharmaceuticals-adil-up-61-today/">Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Jaguar Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/jagx-stock-quote/">JAGX</a>) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-reports-phase-3-ontarget-trial-results-its-cancer">a Phase 3 clinical trial</a>.



This trial covers the use of crofelemer&nbsp;as a treatment for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. Crofelemer&nbsp;is already approved by the Food and Drug Administration (FDA) as a symptomatic relief of diarrhea in adult HIV/AIDS patients getting antiretroviral therapy.



The bad news for investors in JAGX shareholders is this clinical trial failing to meet its primary endpoint. The trial covered 10 different tumor types but crofelemer was only effective in patients with breast and respiratory cancers.



Pablo Okhuysen, Principal Investigator of the OnTarget clinical trial, said the following about the results.




&ldquo;Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a survey that informed us about the appropriate clinical study design and clinical endpoints, that are important to the patients in this prophylactic trial. We will continue to evaluate important OnTarget findings, with further analyses.&rdquo;




<h2>What This Means for JAGX Stock</h2>



The failed clinical trial of crofelemer is a blow to JAGX stock today. This has traders selling shares, triggering heavy trading of the stock. That has more than 12 million units on the move as of this writing. This is already above its daily average trading volume of about 800,000 shares.



JAGX stock is down 55.2% as of Tuesday afternoon.



Investors will want to keep reading for more of the most recent stock market news!



We have all of the hottest market happenings investors need to know about on Tuesday! Among that is what has shares of AMC Entertainment&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>), Adial Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) and CrowdStrike&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) in the news today. All of that info is ready to go at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/wedbush-just-raised-its-price-target-on-amc-entertainment-amc-stock/">Wedbush Just Raised Its Price Target on AMC Entertainment (AMC) Stock</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-adial-pharmaceuticals-adil-up-61-today/">Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/crowdstrike-outage-update-everything-you-need-to-know-as-shutdowns-persist/">CrowdStrike Outage Update: Everything You Need to Know as Shutdowns Persist</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-jaguar-health-jagx-stock-down-55-today/">Why Is Jaguar Health (JAGX) Stock Down 55% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Jaguar Health (JAGX) Stock Down 55% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is falling on Tuesday after the food delivery robot company <a href="https://finance.yahoo.com/news/serve-robotics-announces-pricing-15-131200778.html">priced a private offering for its shares</a>.



Serve Robotics is selling 2.5 million pre-funded warrants for SERV stock for $6 each. On top of that, each of these warrants comes with one warrant to acquire another share. They are exercisable immediately, expire in five years and have an exercise price of $6.



Serve Robotics is expecting to raise gross proceeds of $15 million from this private offering. Aegis Capital Corp is the exclusive placement agent for the offering. Orrick, Herrington &amp; Sutcliffe LLP acted as counsel to SERV while Sichenzia Ross Ference Carmel LLP counseled Aegis Capital Corp.



<h2>What This Means for SERV Stock</h2>



This private offering increases the total number of SERV shares on the market. As a result, it dilutes the stakes of current investors in the company. That&rsquo;s one reason why SERV stock is falling on Tuesday.



Investors likely aren&rsquo;t happy about the offering price, either. At $6 per share, the shares are heavily discounted compared to the stock&rsquo;s prior closing price of $8.77 each. This helps explain why SERV stock is sliding lower on Tuesday.



SERV stock is down 8.2% as of Tuesday morning. That comes with some 27 million shares traded, as compared to a daily average of about 7.4 million shares.



Investors will want to read more of the most recent stock market stories below!



We have all of the hottest stock market news investors need to know about on Tuesday! A few examples include what&rsquo;s going on with shares of Jaguar Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/jagx-stock-quote/">JAGX</a>), AMC Entertainment&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>) and Adial Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) stock. You can read up on all of this at the following links!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-jaguar-health-jagx-stock-down-55-today/">Why Is Jaguar Health (JAGX) Stock Down 55% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/wedbush-just-raised-its-price-target-on-amc-entertainment-amc-stock/">Wedbush Just Raised Its Price Target on AMC Entertainment (AMC) Stock</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-adial-pharmaceuticals-adil-up-61-today/">Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-serve-robotics-serv-stock-down-today/">Why Is Serve Robotics (SERV) Stock Down Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Serve Robotics (SERV) Stock Down Today?

Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals (ADIL – Research Report) yesterday. The company's shares opene...

Maxim Group Keeps Their Hold Rating on Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals, SunPower, and MicroCloud Hologram are the 3 Penny Stocks to watch on July 25, based on&nbsp;TipRanks' Penny Stock Screener t...

3 Penny Stocks to Watch Now, 7/25/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) just reported results for the second quarter of 2024.<ul><li>Adial Pharmaceuticals reported earnings per share of -59 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/adil-stock-earnings-adial-pharmaceuticals-for-q2-of-2024/">ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024

Adial Pharmaceuticals reports Q2 results

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL – Research Report). The com...

Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)

BLRX

CRWD

HOLO

LIFE

RELI

RIVN

SERV

SOLV

SOPA

SPWR

Press Releases

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Events

MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Adial Pharmaceuticals

Adial Pharmaceuticals (ADIL) Forecast

Adial Pharmaceuticals (NASDAQ:ADIL) Stock, Quote.Headers.trade-ideas